Nasal cavity olfactory neuroblastoma

disease
On this page

Also known as olfactory neuroblastoma of nasal cavityolfactory neuroblastoma of the nasal cavity

Summary

Nasal cavity olfactory neuroblastoma (MONDO:0001129) is a disease. A subtype of nasal cavity cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namenasal cavity olfactory neuroblastoma
Mondo IDMONDO:0001129
DOIDDOID:10812
NCITC7604
UMLSC1334923
MedGen233749
GARD0022888
Anatomy (UBERON)UBERON:0001707
Is cancer (heuristic)no

Also known as: nasal cavity olfactory neuroblastoma · olfactory neuroblastoma of nasal cavity · olfactory neuroblastoma of the nasal cavity

Disease family

This is a subtype of nasal cavity cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmcancerrespiratory system cancernasal cavity cancernasal cavity olfactory neuroblastoma

Related subtypes (2): nasal cavity lymphoma, nasal cavity carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.